Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CPB1 | P15086 | 1/20 | 0.41 |
| ▸ | CPA3 | P15088 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | ALPG | P10696 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6446630 | 1.00 | CPA1 (0.43) | CPA1CYP1A2CPB1CPA3CPB2 | |
| SCHEMBL677411 | 1.00 | CPA1 (0.43) | CPA1CYP1A2CPB1CPA3CPB2 | |
| SCHEMBL14264245 | 0.84 | CPA1 (0.62) | CPA1CYP1A2CPB1CPA3CPB2 | |
| SCHEMBL10589550 | 0.81 | CYP1A2 (0.40) | CPA1CYP1A2CPB1CPA3CPB2 | |
| SCHEMBL10799571 | 0.81 | CYP1A2 (0.40) | CPA1CYP1A2CPB1CPA3CPB2 | |
| SCHEMBL1915970 | 0.81 | CPA3 (0.56) | CPA1CYP1A2CPB1CPA3CPB2 | |
| SCHEMBL7328940 | 0.79 | CYP1A2 (0.43) | CPA1CYP1A2CPB1CPA3CPB2 | |
| SCHEMBL902140 | 0.77 | ABCB1 (0.47) | CYP1A2MEN1KMT2ATAAR1NPC1 | |
| SCHEMBL7321758 | 0.77 | TAAR1 (0.44) | CPA1CYP1A2CPB1CPA3CPB2 | |
| SCHEMBL7303541 | 0.77 | CTNNB1 (0.46) | CPA1CYP1A2MEN1KMT2AMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| WO-2010111136-A2 | ALISKIREN MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20090197823-A1 | ALISKIREN MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197823-A1 | ALISKIREN MODULATION OF NEUROGENESIS | DCX, NGF, BDNF | CPA1 2237/4885CYP1A2 4843/4885CPB1 1881/4885 |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | CPA1 4198/4885CYP1A2 4703/4885CPB1 4171/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | CPA1 816/4885CYP1A2 4049/4885CPB1 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.